Harmony Pharma (HRMY) - P/E Multiple

Harmony Pharma - graphic logo of issuer HRMY

Harmony Biosciences focuses on creating advanced therapies for rare CNS pathologies and developing new molecules. The company's monthly P/E dynamics reflect market expectations, with the value stabilizing at 11.20. Risk mitigation is driven by the expanded application of its key drug, while distribution and testing efficiency are supported through the engagement of external contractors.

Harmony Biosciences Holdings, Inc. (HRMY) - Price to Earnings Ratio from 07/04/2022 to 11/16/2026

Analytical breakdowns for Harmony Biosciences

General company analysis:HRMY (Harmony Pharma)
Original product of harmonybiosciences.com

Harmony Biosciences specializes in the commercialization of unique drugs for the therapy of rare neurological disorders, including the treatment of narcolepsy. The ratio of market value to net income digitizes the payback period of capitalization, allowing the P/E valuation trend to determine whether an investor is overpaying for future revenue growth amid regulatory risks and volatility in the biopharmaceutical sector.

Competing companies

Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|XENE - Price to Earnings Ratio|Business Payback Period Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Price to Earnings Ratio|CPRX (Catalyst Pharmaceuticals) - Price to Earnings Ratio|DNLI (denalitherapeutics.com) - P/E Multiple|Price to Earnings Ratio BHVN|Price to Earnings Ratio AMLX (Amylyx Pharmaceuticals, Inc.)|Market Price to Net Income Ratio TRVI|Price to Earnings Ratio Praxis Precision Medicines, Inc. PRAX|Anavex Corp - Price to Earnings Ratio|CBLL: Price to Earnings Ratio|Company Value to Net Income PRTA (prothena.com)|Alector, Inc. (ALEC) - Price to Earnings Ratio|Price to Earnings Multiple ANNX|Price to Earnings Ratio Omeros Corp.|Neurogene Therapeutics (NGNE) - Business Payback Period|P/E Multiple ACIU|VYGR (Voyager Therapeutics) - Company Value to Net Income|P/E Multiple NMRA (neumoratx.com)|SCLX: Price to Earnings Multiple|TVGN - Price to Earnings Ratio|Market Cap to Earnings Alpha Cognition Inc.|CGTX: P/E Multiple|inhibikase.com (IKT) - P/E Multiple|Price to Earnings Ratio Cassava Sciences Inc|ASRT - Market Cap to Net Income Ratio|Price to Earnings Ratio Coya (COYA)|P/E Multiple VistaGen Therapeutics Inc (VTGN)|Ovid Therapeutics Inc. - Price to Earnings Ratio|Business Payback Period Acumen Pharmaceuticals (ABOS)|CervoMed Corporation - P/E Multiple|Business Payback Period alteritytherapeutics.com ATHE|CLNN: P/E Multiple|Market Cap to Earnings PepGen Corp (PEPG)|Price to Earnings Ratio Jupiter Neurosciences, Inc.|RLMD: Company Value to Net Income|P/E Multiple ANVS|Price to Earnings Ratio Grace Tx GRCE|Price to Earnings Ratio Firefly Neuroscience, Inc AIFF|KLTO: Price to Earnings Multiple|NRSN - Price to Earnings Ratio|RVPH: Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|NeurAxis Inc. (NRXS) - P/E Multiple|Price to Earnings Ratio Helius Medical|Passage Bio, Inc. - Market Cap to Net Income|Price to Earnings Ratio NEUP (Neuphoria)|NERV - Market Cap to Earnings|P/E Multiple ATHA (athira.com)|P/E Multiple Addex Therapeutics Ltd ADXN|Alzamend Neuro, Inc. - P/E Multiple|CYCN - P/E Multiple|PTIX (Protagenic Therapeutics, Inc.) - Price to Earnings Ratio|Market Cap to Earnings Pasithea (KTTA)|Price to Earnings Ratio Cortigent|Market Cap to Earnings Avenue Therapeutics Inc. ATXI|Price to Earnings Ratio brainstorm-cell.com (BCLI)|Price to Earnings Ratio Cara Therapeutics, Inc CARA|P/E Multiple CHRO (chromocell.com)|Company Value to Net Income ELYM|Intra-Cellular Therapies Inc. - P/E Multiple|Market Cap to Earnings Longboard Pharmaceuticals Inc|Marinus (MRNS) - Price to Earnings Ratio|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo Pharmaceuticals|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple